Cyxone step up activities and extend collaboration with global CRO around RA trial
Cyxone (publ) announces today that the company has signed a Letter of Agreement (LOA) with the internationally renowned clinical contract research organization (CRO) following on an early operations agreement (EOA) signed last month. The LOA is a key step for advancing the clinical phase 2b trial of Rabeximod in patients with rheumatoid arthritis
The agreement enables Cyxone to expand and intensify start-up activities for the phase 2b trial including site selections and regulatory submissions enabling an efficient route to enrolling patients into the trial within the shortest period of time.
Cyxone is developing Rabeximod, an oral potential second line treatment for patients suffering from the autoimmune disease rheumatoid arthritis (RA) and who do not respond to current standard of care treatments. This underserved patient population represents 25-40% of diagnosed patients. Based on previous preclinical and clinical results, the company is currently preparing for a phase 2b trial of Rabeximod in patients with RA. The trial will be double blind, randomized, placebo controlled consisting of three treatment arms comparing two different dose levels of Rabeximod on top standard treatment with methotrexate alone over a 16-week-treatment period with an 8-week extension and 2-week follow up.
“Following on an early clinical operations agreement which was signed in December, we quickly advance our collaboration with this Letter of Agreement; a signal of commitment from both parties. Cyxone has secured a partner with first-class rheumatoid arthritis trial expertise and a global network of research sites able to deliver efficiently and at the highest level of quality for the phase 2b trial,” comments Tara Heitner, CEO, Cyxone.Contact
Tara Heitner, CEO
Tel: +46 70 781 88 08
211 22 Malmö, Sweden
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, email@example.com. For more information, please visit www.cyxone.comOpen Press release